BACKGROUND: Currently there is no reliable medical treatment for @entity337 ( @entity337 ). METHODS: Thirty-nine @entity35 underwent creation of @entity337 or sham operation. Treated @entity35 were assigned to early or late institution of @entity7855 therapy (100  mg/kg/day) for a total of 10  weeks. Treatment-effects were measured by serial echocardiography, invasive hemodynamic measurements, and tissue analysis. RESULTS: @entity35 assigned to early treatment developed less remodeling than untreated @entity35 . Thus, left ventricular (LV) dilation was blunted by @entity7855 with end-systolic diameter being significantly smaller (6.6      0.4 vs. 7.7      0.4  mm, respectively, p  <  0.05). Also, LV wall thickness was significantly decreased in treated @entity35 compared to controls (2.23      0.08 vs. 2.16      0.05  mm, p  <  0.01). Fractional shortening was improved by treatment (p  <  0.05). @entity296 was borderline decreased by treatment (p  =  0.09). Akt was increased in treated compared to controls (p  <  0.05). CONCLUSION: @entity7855 slightly inhibits LV remodeling and improves fractional shortening in @entity35 with @entity337 when treatment is initiated early.

@entity7855 treatment attenuates ventricular remodeling in an experimental model of XXXX .

@entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'Rats', 'rats'] @entity296 :: ('MESH:D009202', 'Disease') :: ['Myocardial fibrosis'] @entity337 :: ('MESH:D001022', 'Disease') :: ['AR', 'aortic regurgitation'] @entity7855 :: ('MESH:C101426', 'Chemical') :: ['sildenafil', 'Sildenafil']
@entity337 :: (MESH:D001022,Disease) :: ['aortic regurgitation']
